AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27062408 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877 0.2 mg BID
Number of subjects: 224
Study 27062408 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 100 mg QD
Number of subjects: 224
Study 27062408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 27062408 — intervention group
Group type: EXPERIMENTAL
Intervention: K-877
Number of subjects: 224
Study 25052587 — intervention group
Group type: EXPERIMENTAL
Intervention: TV64.6 Gy
Number of subjects: 232
Study 25052587 — intervention group
Group type: EXPERIMENTAL
Intervention: TV43.7 Gy
Number of subjects: 232
Study 25052587 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI at the start of RT
Number of subjects: 232
Study 21862226 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin (OT)
Number of subjects: 10
Study 21862226 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 IU oxytocin (OT)
Number of subjects: 10
Study 21862226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19155056 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg warfarin initiation nomogram
Number of subjects: 414
Study 17355503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-mediated dilatation in migraineurs
Number of subjects: 50
Study 17355503 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-mediated dilatation in nonmigraineurs (control)
Number of subjects: 50
Study 17355503 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation in migraineurs
Number of subjects: 50
Study 17355503 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilatation in nonmigraineurs (control)
Number of subjects: 50
Study 15021442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 319
Study 15021442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 11160543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (two 7000‐microg retinol equivalent doses)
Number of subjects: 464
Study 11160543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 9758015 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol prevention intervention
Number of subjects: 211
Study 9758015 — intervention group
Group type: COMPARATOR
Intervention: Minimal control materials
Number of subjects: 211
Study 8155452 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg and PCA containing morphine
Number of subjects: 57
Study 8155452 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.05 mg mg‐1 of morphine in PCA
Number of subjects: 57
Study 8155452 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo and PCA containing morphine)
Number of subjects: 57
Study 8155452 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol PCA group
Number of subjects: 57
Study 8155452 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol bolus group
Number of subjects: 57
Study 8155452 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 3422519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm IV every 12 hours)
Number of subjects: 53
Study 3422519 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 gm IV every six to eight hours)
Number of subjects: 53
Study 3422519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 53
Study 3422519 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 53
Study 31373077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannula subcision (18 gauge cannula)
Number of subjects: 100
Study 31373077 — intervention group
Group type: COMPARATOR
Intervention: Needle subcision (27 gauge needle)
Number of subjects: 100
Study 29684092 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cycle therapy (SCT; 5 days on, 2 days off ART)
Number of subjects: 199
Study 29684092 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (CT)
Number of subjects: 199
Study 29684092 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cycle therapy (SCT)
Number of subjects: 199
Study 26460894 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence and Adherence Scale for Cognitive Behavioral Therapy (CAS‐CBT)
Number of subjects: 182
Study 25578377 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy (6 cycles)
Number of subjects: 283
Study 25578377 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by eprirubicin/docetaxel (3 cycles each)
Number of subjects: 283
Study 24434090 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing
Number of subjects: 25
Study 24434090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast titration
Number of subjects: 25
Study 24434090 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant-naive patients
Number of subjects: 25
Study 24434090 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dosing
Number of subjects: 25
Study 20625120 — intervention group
Group type: COMPARATOR
Intervention: Control (Arm A): four cycles of mitomycin (8 mg/m(2) on day 1)/vindesine (3 mg/m(2) on days 1, 8)/cisplatin (80 mg/m(2) on day 1) plus TRT 60 Gy
Number of subjects: 0
Study 20625120 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (Arm B): weekly irinotecan (20 mg/m(2))/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of irinotecan (50 mg/m(2) on days 1, 8)/carboplatin (AUC 5 on day 1)
Number of subjects: 0
Study 20625120 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (Arm C): weekly paclitaxel (40 mg/m(2))/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of paclitaxel (200 mg/m(2) on day 1)/carboplatin (AUC 5 on day 1)
Number of subjects: 0
Study 17330626 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole topical gel 0.75%
Number of subjects: 582
Study 15025849 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN ointment
Number of subjects: 40
Study 15025849 — intervention group
Group type: COMPARATOR
Intervention: Control (non-adherent gauzes and bulky gauzes with cloramine solution)
Number of subjects: 40
Study 11448900 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine (40 microg, bound to alum as an adjuvant)
Number of subjects: 38
Study 11448900 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine (human albumin, bound to alum as an adjuvant)
Number of subjects: 38
Study 11448900 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine
Number of subjects: 38
Study 11448900 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 38
Study 9697011 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led condition (TL; n = 16)
Number of subjects: 61
Study 9697011 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial self-help condition (PSH; n = 19)
Number of subjects: 61
Study 9697011 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-help condition (SH; n = 15)
Number of subjects: 61
Study 9697011 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (WL; n = 11)
Number of subjects: 61
Study 8275733 — intervention group
Group type: EXPERIMENTAL
Intervention: 167-ml chamber device (Device A)
Number of subjects: 48
Study 8275733 — intervention group
Group type: EXPERIMENTAL
Intervention: 700-ml chamber device (Device B)
Number of subjects: 48
Study 8275733 — intervention group
Group type: COMPARATOR
Intervention: nonchamber device (Device C)
Number of subjects: 48
Study 8275733 — intervention group
Group type: COMPARATOR
Intervention: nonchamber device (Device D)
Number of subjects: 48
Study 3050853 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms dose of H. influenzae type b PRP vaccine
Number of subjects: 223
Study 3050853 — intervention group
Group type: COMPARATOR
Intervention: 12.5 micrograms dose of H. influenzae type b PRP vaccine (used in 1974)
Number of subjects: 223
Study 3050853 — intervention group
Group type: COMPARATOR
Intervention: Comparison to 1974 vaccinations
Number of subjects: 223
Study 17894054 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage of pizotyline
Number of subjects: 100
Study 17894054 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 100
Study 17894054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dosage of pizotyline
Number of subjects: 100
Study 28829670 — intervention group
Group type: EXPERIMENTAL
Intervention: PKP combined with aclasta (zoledronic acid)
Number of subjects: 104
Study 28829670 — intervention group
Group type: COMPARATOR
Intervention: PKP (control group)
Number of subjects: 104
Study 27225761 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline catecholamine levels indexed by pupil diameter
Number of subjects: 48
Study 27225761 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine transporter blocker atomoxetine
Number of subjects: 48
Study 25773565 — intervention group
Group type: EXPERIMENTAL
Intervention: Global rating of improvement
Number of subjects: 52
Study 25773565 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence-specific HRQOL instrument
Number of subjects: 52
Study 25773565 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic preference-based HRQOL outcome
Number of subjects: 52
Study 23864720 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI patients
Number of subjects: 0
Study 23864720 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 20180694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sootshekhar Rasa (250 mg) plus Sitopaladi Churna (400 mg) daily for 90 days
Number of subjects: 1322
Study 20180694 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid tablet for 90 days
Number of subjects: 1322
Study 20180694 — intervention group
Group type: COMPARATOR
Intervention: Control group (starch)
Number of subjects: 1322
Study 17560819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse follow-up intervention (home visits every 4th month for 2 years, total 7 visits)
Number of subjects: 102
Study 17560819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse follow-up intervention
Number of subjects: 102
Study 17560819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 16996826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose followed by 10 mg daily
Number of subjects: 13000
Study 16996826 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose followed by 75 mg daily
Number of subjects: 13000
Study 16996826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13000
Study 16996826 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13000
Study 15851823 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 12
Study 15851823 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 12
Study 11211168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU for 3 months)
Number of subjects: 0
Study 11211168 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 11211168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic cohort
Number of subjects: 0
Study 9772136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (VA) supplementation (210 μmol)
Number of subjects: 0
Study 9772136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7996292 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis model (n = 43)
Number of subjects: 84
Study 7996292 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical work-up for pulmonary embolism (control group, n = 41)
Number of subjects: 84
Study 7996292 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis model
Number of subjects: 84
Study 3050300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 25
Study 3050300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15343351 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 32
Study 15343351 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 32
Study 30281924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (300 μg oral dose)
Number of subjects: 35
Study 28968304 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone dispatcher-assisted CPR (T-CPR) in untrained guided group (n=32)
Number of subjects: 115
Study 28968304 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone dispatcher-assisted CPR (T-CPR) in trained guided group (n=30)
Number of subjects: 115
Study 28968304 — intervention group
Group type: COMPARATOR
Intervention: No T-CPR in untrained nonguided group (n=27)
Number of subjects: 115
Study 28968304 — intervention group
Group type: COMPARATOR
Intervention: No T-CPR in trained nonguided group (n=26)
Number of subjects: 115
Study 24745630 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm long TISAD/TAD
Number of subjects: 0
Study 24745630 — intervention group
Group type: COMPARATOR
Intervention: 6-mm long TISAD/TAD
Number of subjects: 0
Study 23163910 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 540
Study 23163910 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 10 mg
Number of subjects: 540
Study 23163910 — intervention group
Group type: COMPARATOR
Intervention: linagliptin 5 mg and 10 mg
Number of subjects: 540
Study 21450089 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a vocational rehabilitation (VR) service
Number of subjects: 0
Study 21450089 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no formal employment support)
Number of subjects: 0
Study 21450089 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a VR service
Number of subjects: 0
Study 19251137 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (AcrySof toric IOL) implantation
Number of subjects: 40
Study 19251137 — intervention group
Group type: COMPARATOR
Intervention: Paired opposite clear corneal incisions (OCCIs) with spherical IOL implantation
Number of subjects: 40
Study 16452736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate at a dosage of 10 mg/day for six months
Number of subjects: 60
Study 16452736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alendronate)
Number of subjects: 60
Study 15212653 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.017 mg/kg/week for 1 month, then 0.033 mg/kg/week)
Number of subjects: 31
Study 15212653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15212653 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (open study after 6 months)
Number of subjects: 31
Study 11301961 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 11301961 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 9215240 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of peanut extract (0.5 ml of 1:100 wt/vol peanut extract)
Number of subjects: 12
Study 9215240 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 12
Study 9215240 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of peanut extract
Number of subjects: 12
Study 8305355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg t.d.s.
Number of subjects: 192
Study 8305355 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine 10 mg t.d.s.
Number of subjects: 192
Study 8305355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 192
Study 3566820 — intervention group
Group type: EXPERIMENTAL
Intervention: Inservice training program for public health nurses
Number of subjects: 158
Study 3566820 — intervention group
Group type: COMPARATOR
Intervention: Control group (nurses not in the experimental group)
Number of subjects: 158
Study 31539818 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% AA group
Number of subjects: 16
Study 31539818 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% AA group
Number of subjects: 16
Study 30938751 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive trust-enhanced e-consent
Number of subjects: 734
Study 30938751 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive-only e-consent
Number of subjects: 734
Study 30938751 — intervention group
Group type: COMPARATOR
Intervention: Standard e-consent (no interactivity, no trust enhancement)
Number of subjects: 734
Study 28577171 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc (SIMS)
Number of subjects: 193
Study 28577171 — intervention group
Group type: COMPARATOR
Intervention: Monarc (SMUS)
Number of subjects: 193
Study 26578315 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load (N-Back task)
Number of subjects: 20
Study 26578315 — intervention group
Group type: COMPARATOR
Intervention: Low cognitive load (N-Back task)
Number of subjects: 20
Study 25632625 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon assisted Valsalva maneuver (PBAV)
Number of subjects: 40
Study 25632625 — intervention group
Group type: COMPARATOR
Intervention: Conventional Valsalva maneuver (CV)
Number of subjects: 40
Study 22549085 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwers Ten (TT)
Number of subjects: 68
Study 22549085 — intervention group
Group type: EXPERIMENTAL
Intervention: Keiser Pneumatic (KP)
Number of subjects: 68
Study 22549085 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric (PLY)
Number of subjects: 68
Study 22549085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 19745828 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 35
Study 19745828 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 35
Study 19759992 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary allied health education course for allied health students
Number of subjects: 1300000
Study 15891523 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene exposure
Number of subjects: 0
Study 11641293 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplement to increase protein intake to 25% energy
Number of subjects: 41
Study 11641293 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium supplement to provide an additional 12 g soluble fiber/d
Number of subjects: 41
Study 11641293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protein and fiber supplements
Number of subjects: 41
Study 11641293 — intervention group
Group type: COMPARATOR
Intervention: Low-protein, low-fiber diet (control)
Number of subjects: 41
Study 9677603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) children
Number of subjects: 2470
Study 9677603 — intervention group
Group type: EXPERIMENTAL
Intervention: Term low birth weight (LBW) children
Number of subjects: 2470
Study 7977173 — intervention group
Group type: COMPARATOR
Intervention: Ondansentron (5‐HT3) alone
Number of subjects: 0
Study 7977173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansentron (5‐HT3) plus alprazolam (APZ)
Number of subjects: 0
Study 2686456 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives (ethinyl estradiol and levonorgestrel)
Number of subjects: 130
Study 2686456 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives (ethinyl estradiol and norethindrone)
Number of subjects: 130
Study 2686456 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives (all formulations)
Number of subjects: 130
Study 2686456 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonhormonal methods)
Number of subjects: 130
Study 2686456 — intervention group
Group type: EXPERIMENTAL
Intervention: All triphasic oral contraceptives
Number of subjects: 130
Study 4931488 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 11
Study 4931488 — intervention group
Group type: EXPERIMENTAL
Intervention: Phetharbital
Number of subjects: 11
Study 30051179 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 1541
Study 30051179 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF
Number of subjects: 1541
Study 30051179 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R
Number of subjects: 1541
Study 30051179 — intervention group
Group type: EXPERIMENTAL
Intervention: ALCAM
Number of subjects: 1541
Study 30051179 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulysin
Number of subjects: 1541
Study 30051179 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa treatment
Number of subjects: 1541
Study 28676236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28676236 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (nifedipine controlled-release tablet)
Number of subjects: 80
Study 26041510 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee OA-insomnia group
Number of subjects: 208
Study 26041510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sleep efficiency and high catastrophizing scores
Number of subjects: 208
Study 26041510 — intervention group
Group type: EXPERIMENTAL
Intervention: Central sensitization (CS)
Number of subjects: 208
Study 26041510 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 208
Study 22491388 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials for bottle weaning
Number of subjects: 26
Study 22491388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling sessions with educational materials
Number of subjects: 26
Study 21224234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of l‐carnitine‐l‐tartrate and 80 g of CHO (Carnitine)
Number of subjects: 14
Study 21224234 — intervention group
Group type: COMPARATOR
Intervention: 80 g of CHO (Control)
Number of subjects: 14
Study 19545216 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 0
Study 19545216 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study 18184521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 79
Study 18184521 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride
Number of subjects: 79